SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT00187512
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.

Key Dates

Start date
Mar 31, 2000
Status verified
Jul 2025
Primary completion
Dec 31, 2032
Completion
Dec 31, 2033

Study Design

Enrollment
2,500 participants (estimated)

Primary Outcome Measure

The general theme of this core is to investigate the relationship between the virologic response to antiretroviral therapy and clinical outcome. [ Time Frame: Ongoing ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
San Francisco General HospitalSan FranciscoCalifornia94110
Rebecca Hoh, M.S.
[email protected]
415-476-4082
Montha Pao
[email protected]
415-476-4082
Steven G. Deeks, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By condition
HIV
By specialty
Infectious disease
By research site
San Francisco General Hospital· San Francisco, CA

Related Studies